About this trial
Mitral insufficiency (MI) accounts for 24% of adult valvulopathies and affects 7% of subjects older than 75 years. They are the second leading cause of valvulopathy in Europe. The most common etiology is the associated valvular prolapse. Mitral surgery remains the reference treatment for symptomatic MI. The success of this procedure depends on the mitral valve geometry and the location of the prolapse. The site of the prolapse, whether monovalvular, localized to the posterior or anterior leaflet, or bivalvular, influences the possibilities and probably the long-term results of the plasty.
Eligibility criteria
Qualifiers
Patients operated between 1988 and 2011
Presence of a valvular prolapse diagnosed by echocardiography
Possibility of a complete clinical evaluation at the time of the initial echocardiography
Disqualifiers
Ischemic MI (including papillary muscle rupture)
Presence of significant aortic valvulopathy, mitral valvular stenosis or congenital disease
History of cardiac surgery
Trial design
Treatments tested in this trial
- Not listed